Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

·1 min read
  • Cyclerion Therapeutics Inc (NASDAQ: CYCN) and Beacon Biosignals have expanded strategic partnerships between the two companies.

  • This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide Cyclerion's CY6463 and CY3018 programs for neurological diseases associated with cognitive impairment.

  • Beacon Biosignals' electroencephalogram (EEG) neurobiomarker platform is engineered to discover and scale new clinical paradigms for neurological and psychiatric diseases.

  • The companies previously collaborated on analyzing data from a Cyclerion clinical translational pharmacology study of CY6463.

  • CY6463 lead candidate is an oral central nervous system (CNS)-penetrant sGC stimulator.

  • Initial data from CY6463 trials have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid.

  • In addition, CY6463 resulted in promising impacts on EEG measures, neuroinflammation, and other neurophysiological measures that support continued clinical development.

  • Further evaluation of CY6463 in Alzheimer's disease with vascular pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes are ongoing.

  • A study in Cognitive Impairment Associated with Schizophrenia is expected to initiate shortly.

  • Price Action: CYCN shares closed at $3.68 on Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting